Fennec Pharma Narrows Q2 Loss, PEDMARK Sales Up Amidst Cash Burn

TL;DR

**FENC is burning cash despite growing PEDMARK sales, making it a risky bet without a clear path to sustained profitability.**

AI Summary

FENNEC PHARMACEUTICALS INC. reported a net loss of $3.15 million for the three months ended June 30, 2025, an improvement from a net loss of $5.55 million in the same period of 2024. For the six months ended June 30, 2025, the company posted a net loss of $4.32 million, a significant decline from a net income of $7.28 million in the prior year, primarily due to the absence of a $17.96 million licensing revenue recognized in 2024. PEDMARK product sales, net, increased to $9.65 million for the three months ended June 30, 2025, up from $7.26 million in 2024, and rose to $18.40 million for the six months ended June 30, 2025, compared to $14.68 million in 2024. Operating expenses for the six months ended June 30, 2025, decreased to $21.94 million from $23.94 million in 2024, driven by lower selling and marketing expenses. The company's cash and cash equivalents decreased from $26.63 million at December 31, 2024, to $18.71 million at June 30, 2025, with negative cash flows from operating activities of $8.00 million for the six-month period. Fennec believes its current funds, including a $43.00 million upfront payment from Norgine, are sufficient for planned activities for at least the next twelve months.

Why It Matters

For investors, Fennec's continued net losses and negative operating cash flow, despite increased PEDMARK sales, signal ongoing financial challenges. The absence of significant licensing revenue, which boosted 2024's net income, highlights the reliance on product sales for future growth. Employees and customers benefit from the commercialization of PEDMARK, an FDA-approved product, but the company's financial health could impact long-term stability and innovation. In the competitive biopharmaceutical market, Fennec's ability to convert increased product sales into profitability and sustain its operations beyond the next 12 months, as projected, will be critical for its market position.

Risk Assessment

Risk Level: high — The company reported a net loss of $4.32 million for the six months ended June 30, 2025, and experienced negative cash flows from operating activities of $8.00 million for the same period. Furthermore, Fennec has an accumulated deficit of $223.99 million as of June 30, 2025, indicating a history of unprofitability and significant financial risk.

Analyst Insight

Investors should exercise caution and closely monitor Fennec's cash burn rate and progress towards profitability. While PEDMARK sales are growing, the company's ability to generate positive operating cash flow and reduce its accumulated deficit will be key indicators for future investment decisions.

Financial Highlights

debt To Equity

N/A

revenue

$18.40M

operating Margin

-19.2%

total Assets

$44.88M

total Debt

$31.41M

net Income

-$4.32M

eps

N/A

gross Margin

N/A

cash Position

$18.71M

revenue Growth

+25.3%

Revenue Breakdown

Key Numbers

• $3.15M — Net loss for Q2 2025 (Improved from $5.55M net loss in Q2 2024)
• $4.32M — Net loss for H1 2025 (Compared to $7.28M net income in H1 2024)
• $18.40M — PEDMARK product sales for H1 2025 (Increased from $14.68M in H1 2024)
• $18.71M — Cash and cash equivalents at June 30, 2025 (Decreased from $26.63M at Dec 31, 2024)
• $8.00M — Negative cash flow from operating activities for H1 2025 (Indicates significant cash burn)
• $223.99M — Accumulated deficit at June 30, 2025 (Reflects historical losses)
• $43.00M — Upfront payment from Norgine (Provides liquidity for the next 12 months)
• 27,831,698 — Common shares outstanding as of August 11, 2025 (Total shares in circulation)

Key Players & Entities

• FENNEC PHARMACEUTICALS INC. (company) — Registrant
• PEDMARK (product) — FDA, EMA and U.K. approved product
• Norgine Pharma UK Limited (company) — Exclusive licensing agreement partner
• Petrichor Opportunities Fund I LP (company) — Securities Purchase Agreement counterparty
• Nasdaq Capital Market (market) — Exchange for common shares
• FDA (regulator) — Approved PEDMARK
• EMA (regulator) — Approved PEDMARK
• SEC (regulator) — Securities and Exchange Commission

FAQ

Risk Factors

• Cash Burn and Liquidity [high — financial]: The company experienced negative cash flow from operating activities of $8.00 million for the six months ended June 30, 2025. Cash and cash equivalents decreased from $26.63 million at December 31, 2024, to $18.71 million at June 30, 2025. While the $43.00 million upfront payment from Norgine is expected to provide sufficient funds for at least the next twelve months, continued operational losses could strain liquidity.
• Accumulated Deficit [medium — financial]: Fennec Pharmaceuticals has an accumulated deficit of $223.99 million as of June 30, 2025. This reflects a history of net losses, indicating that the company has not yet achieved sustained profitability.
• Dependence on PEDMARK Sales [medium — operational]: The company's revenue is increasingly reliant on PEDMARK product sales, which generated $18.40 million in the first six months of 2025. Any disruption in the manufacturing, marketing, or sales of PEDMARK could materially impact financial performance.
• Debt Obligations [medium — financial]: The company has total liabilities of $52.34 million as of June 30, 2025, including a term loan of $18.21 million. While not excessively leveraged, managing debt service obligations is crucial, especially given the current cash burn.
• Product Approval and Market Access [medium — regulatory]: The success of Fennec Pharmaceuticals is tied to the regulatory approval and market access of its products, particularly PEDMARK. Changes in regulatory requirements or reimbursement policies could adversely affect revenue and profitability.

Industry Context

Fennec Pharmaceuticals operates in the highly competitive biopharmaceutical sector, focusing on orphan drugs. The industry is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight from bodies like the FDA. Success often hinges on securing intellectual property, achieving regulatory approvals, and establishing effective commercialization strategies, particularly for niche markets like rare diseases.

Regulatory Implications

Fennec's operations are subject to the rigorous regulatory framework governing pharmaceutical products. Maintaining compliance with FDA regulations for manufacturing, marketing, and post-market surveillance of PEDMARK is critical. Any adverse regulatory actions or changes in approval requirements could significantly impact the company's ability to generate revenue and operate.

What Investors Should Do

1. Monitor cash burn rate and runway.
2. Analyze PEDMARK sales trajectory.
3. Evaluate the impact of the absence of licensing revenue.
4. Assess the company's long-term profitability path.

Key Dates

• 2025-06-30: End of Second Quarter and First Six Months — Reporting period for the condensed consolidated financial statements, showing improved quarterly net loss but a significant year-over-year decline in six-month net income due to licensing revenue.
• 2025-08-11: Common Shares Outstanding Date — Provides the most current number of shares in circulation (27,831,698), relevant for per-share calculations and market capitalization.
• 2024-12-31: End of Fiscal Year 2024 — Baseline for comparison of cash and cash equivalents, which decreased from $26.63 million to $18.71 million by June 30, 2025.

Glossary

PEDMARK product sales, net

Revenue generated from the sale of the company's product, PEDMARK, after deducting any returns, allowances, and discounts. (This is the primary source of ongoing revenue for Fennec Pharmaceuticals, showing growth in the current periods.)

Accumulated deficit

The cumulative net losses of a company since its inception, minus any cumulative net income. It represents a deficit in equity. (Indicates Fennec's history of unprofitability, standing at $223.99 million as of June 30, 2025.)

Cash and cash equivalents

Highly liquid investments with maturities of three months or less at the time of purchase. Includes cash on hand, bank deposits, and money market funds. (Represents the company's immediate liquidity, which decreased to $18.71 million by June 30, 2025.)

Operating lease liability - current

The portion of a company's obligation to make payments under an operating lease that is due within one year. (This liability was minimal ($2) at the end of 2024 and is not present as of June 30, 2025, indicating no significant short-term lease obligations.)

PIK interest

Payment-In-Kind interest, where interest is paid in the form of additional debt rather than cash. (A component of the company's long-term liabilities, amounting to $1.27 million, which does not require immediate cash outflow for interest payments.)

Year-Over-Year Comparison

Compared to the prior year's six-month period, Fennec Pharmaceuticals saw a significant increase in PEDMARK product sales, rising by 25.3% to $18.40 million. However, total revenue for the six months ended June 30, 2025, decreased substantially to $18.40 million from $32.64 million in the prior year, primarily due to the absence of $17.96 million in licensing revenue recognized in 2024. Operating expenses decreased by approximately 8.3% to $21.94 million, driven by lower selling and marketing costs. The company's cash position has weakened, declining from $26.63 million at the end of 2024 to $18.71 million, accompanied by negative operating cash flows.

Filing Documents

• fencf-20250630x10q.htm (10-Q) — 1493KB
• fencf-20250630xex31d1.htm (EX-31.1) — 14KB
• fencf-20250630xex31d2.htm (EX-31.2) — 18KB
• fencf-20250630xex32d1.htm (EX-32.1) — 9KB
• fencf-20250630xex99d1.htm (EX-99.1) — 305KB
• fencf-20250630xex99d1001.jpg (GRAPHIC) — 3KB
• fencf-20250630xex99d1002.jpg (GRAPHIC) — 1KB
• fencf-20250630xex99d1003.jpg (GRAPHIC) — 3KB
• 0001558370-25-011552.txt ( ) — 6851KB
• fencf-20250630.xsd (EX-101.SCH) — 49KB
• fencf-20250630_cal.xml (EX-101.CAL) — 39KB
• fencf-20250630_def.xml (EX-101.DEF) — 195KB
• fencf-20250630_lab.xml (EX-101.LAB) — 336KB
• fencf-20250630_pre.xml (EX-101.PRE) — 305KB
• fencf-20250630x10q_htm.xml (XML) — 1157KB

: FINANCIAL INFORMATION

PART I: FINANCIAL INFORMATION 3

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets (Unaudited) as of June 30, 2025 and December 31, 2024 3 Condensed Consolidated Statements of Operations (Unaudited) for the Three and Six Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity (Deficit) (Unaudited) for the Three and Six Months Ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows (Unaudited) for the Six Months Ended June 30, 2025 and 2024 6 Notes to the Condensed Consolidated Financial Statements 7

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 24

Quantitative and Qualitative Disclosures about Market Risk

Item 3. Quantitative and Qualitative Disclosures about Market Risk 33

Controls and Procedures

Item 4. Controls and Procedures 33

: OTHER INFORMATION

PART II: OTHER INFORMATION 33

Legal Proceedings

Item 1. Legal Proceedings 33

Risk Factors

Item 1A. Risk Factors 35

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 35

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 35

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 35

Other Information

Item 5. Other Information 35

Exhibits

Item 6. Exhibits 35

Signatures

Signatures 37 Table of Contents PART 1: FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Fennec Pharmaceuticals Inc. Condensed Consolidated Balance Sheets (U.S. Dollars and shares in thousands) (Unaudited) June 30, 2025 December 31, 2024 Assets Current assets Cash and cash equivalents $ 18,705 $ 26,634 Accounts receivable, net 17,502 12,884 Prepaid expenses 1,421 3,080 Inventory 2,201 1,060 Other current assets 965 466 Total current assets 40,794 44,124 Non-current assets Non-current accounts receivable, net 3,314 — Other non-current assets, net of amortization 768 822 Total non-current assets 4,082 822 Total assets $ 44,876 $ 44,946 Liabilities and stockholders' deficit Current liabilities: Accounts payable $ 5,941 $ 3,241 Accrued liabilities 2,225 3,428 Contract liability - current 248 248 Operating lease liability - current — 2 Total current liabilities 8,414 6,919 Long-term liabilities Term loan 18,206 18,206 PIK interest 1,271 1,271 Debt discount ( 113 ) ( 139 ) Contract liability - long-term 24,561 24,561 Total long-term liabilities 43,925 43,899 Total liabilities 52,339 50,818 Commitments and contingencies (Note 6) Stockholders' deficit: Common stock, no par value; unlimited shares authorized; 27,733 shares issued and outstanding (2024 27,527 ) 146,165 145,608 Additional paid-in capital 69,127 66,958 Accumulated deficit ( 223,998 ) ( 219,681 ) Accumulated other comprehensive income 1,243 1,243 Total stockholders' deficit ( 7,463 ) ( 5,872 ) Total liabilities and stockholders' deficit $ 44,876 $ 44,946 The accompanying notes are an integral part of these unaudited condensed consolidated financial statements. 3 Table of Contents Fennec Pharmaceuticals Inc. Condensed Consolidated Statements of Operations (U.S. Dollars and shares in thousands, except per share amounts) (Unaudited) Three Months Ended Six Months Ended June 30, June 30,

View Full Filing

View this 10-Q filing on SEC EDGAR